Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 450 Day CR rate
View:
Post by Eoganacht on Sep 02, 2023 5:56pm

450 Day CR rate

Looking at the new swimmer's plot - there is 1 CR patient at 360 days awaiting their 450 day assessment. There are also 3 CR patients at 270 days and 4 CR patients at 180 days awaiting further assessment. All of these patients have had a CR since they were first tested. In 9 months, if they all maintain their CRs we will have a 40% CR rate at 450 days.
Comment by DJDawg on Sep 02, 2023 9:42pm
Based on the data to date, here is the probability for the perfect streak CR patients. Perfect CR from 90-360: 100% chance of staying CR at 450 Perfect CR from 90 to 270: 91% chance of staying CR till 450 Perfect CR from 90 to 180: 75% chance of staying CR till 450 So by my math: - the one CR at 360 stays CR - the 3 patients at 270 will likely convert to 3 CR's for the rest of the study ...more  
Comment by Eoganacht on Sep 02, 2023 11:30pm
Thanks. Taking this into account would mean a 36% 450 day CR rate in 9 months. At that point 53 patients will have been assessed at 450 days.  The final 47 patients should do better than the first 53 because there should be no undertreated patients. So maybe a 40% 450 day CR rate at the end of the trial?
Comment by enriquesuave on Sep 03, 2023 8:39am
40-45% CR at 450 days could very well be reached if we also get a few IR patients to convert to CR.
Comment by 99942Apophis on Sep 03, 2023 9:14am
Am I wrong that yes CR is what we want for end of study trial but the FDA  also views IR + CR as important results as a third treatment could move a few patients into a solid CR classification? 
Comment by Galaxym31 on Sep 04, 2023 3:29pm
The goal should be to extend life time without signifigant side effects .What is the extent of the cancer outside of CR .
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250